– USA, MI – Rockwell Medical, Inc. (NASDAQ: RMTI), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease, today announced the appointment of John P. McLaughlin as its Chairman of the Board, effective immediately. Mr. McLaughlin, who joined the Board on September 5, 2019, succeeds Benjamin Wolin, who will remain on the Board of Directors.
“This is a truly pivotal time for Rockwell Medical with the recent commercial launch of Dialysate Triferic and the filing for approval of I.V. Triferic. I am honored to serve as Chairman of the Board of Directors and look forward to working with the rest of Rockwell Medical’s talented Board and management team as the Company works to transform anemia management in a variety of disease states around the globe and establish Triferic as the standard of care for anemia management in ESRD patients. We are grateful to Ben for his service as Chairman, and we are excited that he will remain an active member of the Board,” said John P. McLaughlin, Chairman of the Board.
About John McLaughlin
Mr. McLaughlin currently also serves on the Board of PDL BioPharma, Inc. where he was Chief Executive Officer for 10 years; Noden Pharma DAC, a Dublin-based pharma company that commercializes hypertension drugs worldwide; and Lensar Inc., a medical technology company that commercializes lasers for refractive cataract surgery worldwide. He has previously co-founded and sold, as well as served on the boards of, a number of biotechnology and medical technology companies.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease and chronic kidney disease. Rockwell Medical’s exclusive renal drug therapy, Triferic, supports disease management initiatives to improve the quality of life and care of dialysis patients and is intended to deliver safe and effective therapy while decreasing drug administration costs and improving patient convenience. The Company has developed multiple formulations of Triferic: Dialysate Triferic; and I.V. Triferic. Dialysate Triferic is the only FDA-approved therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. The Company’s strategy is to bring its therapeutics to market in the United States and to utilize partners to develop and commercialize such therapeutics in international markets. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
For more information: https://www.rockwellmed.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
